Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ORIC-114 |
Synonyms | |
Therapy Description |
ORIC-114 is an inhibitor of EGFR and ERBB2 (HER2) targeting exon 20 insertions, which penetrates the blood brain barrier, and may inhibit EGFR phosphorylation and downstream signaling, potentially resulting in anti-tumor activity (Cancer Res 2021;81(13_Suppl):Abstract nr 1466). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ORIC-114 | ORIC114|ORIC 114 | EGFR Inhibitor (Pan) 62 HER2 Inhibitor 42 | ORIC-114 is an inhibitor of EGFR and ERBB2 (HER2) targeting exon 20 insertions, which penetrates the blood brain barrier, and may inhibit EGFR phosphorylation and downstream signaling, potentially resulting in anti-tumor activity (Cancer Res 2021;81(13_Suppl):Abstract nr 1466). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05315700 | Phase Ib/II | Carboplatin + ORIC-114 + Pemetrexed Disodium ORIC-114 | Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Recruiting | USA | POL | GBR | CAN | AUS | 3 |